Next 10 |
home / stock / crbu / crbu articles
At the RBC Global Healthcare Conference, held on 14-15 May, RBC’s Healthcare Desk Sector Strategist gauged biotech investor sentime...
NEW YORK, April 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigat...
BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing bio...
The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, but the index remained in the "Greed" zone on...
U.S. stocks traded higher toward the end of trading, with the S&P 500 index gaining over 1% on Tuesday. The Dow traded up 0.74% to 39,057....
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. Asana reported quarterly losse...
BERKELEY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing bio...
-- Tim Kelly to lead Caribou's technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and ...
U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday. Shares of Ross Stores, Inc. (NASDAQ: ROST) surged during Frid...
News, Short Squeeze, Breakout and More Instantly...
Caribou Biosciences Inc. Company Name:
CRBU Stock Symbol:
NASDAQ Market:
At the RBC Global Healthcare Conference, held on 14-15 May, RBC’s Healthcare Desk Sector Strategist gauged biotech investor sentime...
2024-05-16 16:30:03 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CRBU on May 16, 2024 02:01PM ET. The previous analyst recommendation was Underperform. CRBU was trading at $3.585 at issue of the analyst recommendation. The overall analyst consensus :...
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Pha...